CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 152 enrolled
Drug / intervention
Durvalumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04774380
NCT04774380Phase 3Completed
CompareCT.gov

A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)

AstraZeneca·interventional·Posted Mar 1, 2021·Updated May 23, 2025

In Brief

A Phase 3 clinical trial evaluating Durvalumab, Cisplatin, and 2 other interventions for Extensive-stage Small Cell Lung Cancer. Completed, enrolled 152 participants across 35 sites in 6 countries.

Detailed Summary

Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive-stage Small Cell Lung Cancer
CountriesBulgaria, Canada, Czechia, Germany, Italy, Turkey (Türkiye)
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMar 1, 2021
Enrollment StartNov 11, 2021
Primary CompletionJun 12, 2023
Study CompletionJan 2, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.3 years ago

Interventions

Durvalumabdrug

Participants will receive durvalumab via IV infusion on Day 1 of each cycle.

Cisplatindrug

Participants will receive cisplatin via IV administration on Day 1 of each cycle.

Carboplatindrug

Participants will receive carboplatin via IV administration Day 1 of each cycle.

Etoposidedrug

Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.